Cargando…
ENHANZE(®) drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20
ENHANZE(®) drug delivery technology is based on the proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20; Halozyme Therapeutics, Inc.) that facilitates the subcutaneous (SC) delivery of co‐administered therapeutics. rHuPH20 works by degrading the glycosaminoglycan hyaluronan (HA), which...
Autores principales: | Locke, Kenneth W., Maneval, Daniel C., LaBarre, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394283/ https://www.ncbi.nlm.nih.gov/pubmed/30744432 http://dx.doi.org/10.1080/10717544.2018.1551442 |
Ejemplares similares
-
Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration
por: Rosengren, Sanna, et al.
Publicado: (2015) -
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
por: Infante, Jeffrey R, et al.
Publicado: (2018) -
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
por: Infante, Jeffrey R, et al.
Publicado: (2018) -
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers
por: Printz, Marie A., et al.
Publicado: (2020) -
Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model
por: Connor, Robert J., et al.
Publicado: (2023)